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Abstract
Background: Survivors of anterior MI are at increased risk for stroke with predilection to form ventricular thrombus.
Commonly patients are discharged on dual antiplatelet therapy. Given the frequency of early coronary reperfusion and risk
of bleeding, it remains uncertain whether anticoagulation offers additional utility. We examined the effectiveness of
anticoagulation therapy for the prevention of stroke after anterior MI.
Methods and Findings: We performed a population-based cohort analysis of 10,383 patients who survived hospitalization
for an acute MI in Ontario, Canada from April 1, 1999 to March 31, 2001. The primary outcome was four-year ischemic stroke
rates compared between anterior and non-anterior MI patients. Risk factors for stroke were assessed by multivariate Cox
proportional-hazards analysis. Warfarin use was determined at discharge and followed for 90 days among a subset of
patients aged 66 and older (n=1483). Among the 10,383 patients studied, 2,942 patients survived hospitalization for an
anterior MI and 20% were discharged on anticoagulation therapy. Within 4 years, 169 patients (5.7%) were admitted with an
ischemic stroke, half of which occurred within 1-year post-MI. There was no significant difference in stroke rate between
anterior and non-anterior MI patients. The use of warfarin up to 90 days was not associated with stroke protection after
anterior MI (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.37–1.26). The use of angiotensin-converting-enzyme
inhibitors (HR, 0.65; 95% CI, 0.44–0.95) and beta-blockers (HR, 0.60; 95% CI, 0.41–0.87) were associated with a significant
decrease in stroke risk. There was no significant difference in bleeding-related hospitalizations in patients who used warfarin
for up to 90 days post-MI.
Conclusion: Many practitioners still consider a large anterior-wall MI as high risk for potential LV thrombus formation and
stroke. Among a cohort of elderly patients who survived an anterior MI there was no benefit from the use of warfarin up to
90 days post-MI to prevent ischemic stroke. Our data suggests that routine anticoagulation of patients with anterior-wall MI
may not be indicated. Prospective randomized trials are needed to determine the optimal antithrombin strategy for
preventing this common and serious adverse outcome.
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Introduction
Patients with acute ST-segment elevation myocardial infarction
(STEMI) have an elevated risk of stroke, most of which are
ischemic in origin [1]. The risk for stroke after myocardial
infarction (MI) is estimated to be 44-fold higher within the first 30
days, and remains 2 to 3 times higher than expected during the
subsequent 3 years [1]. Longitudinal stroke risk following an MI is
estimated to be approximately 1 percent by the first month, 2
percent by one year, and 5 percent by four years [2,3,4].
The association between the size, severity, and location of an MI
and risk of developing stroke remains controversial [5–14];
nonetheless, practice guidelines recommend anticoagulation in
certain settings [15]. For instance, left ventricular (LV) thrombus
formation after an MI poses an increased risk of cardioembolism,
which is reduced by anticoagulation [7,14,16–25]. Anterior-wall
location of a MI has historically been considered a surrogate marker
for potential focal dyskinesia leading to LV aneurysm or thrombus
complication, which some estimate occurs in approximately one-
third of individuals within the first 2 weeks following an anterior MI
[26].Myocardial infarction treatmentpatterns and subsequent post-
MI complications have evolved dramatically in the past 20 years,
particularly with regard to effectiveness and expediency in
medication use, revascularization, ventricular imaging, and hospital
discharge. As a result, practice patterns vary on whether or not
anterior MI alone warrants anticoagulation in an era of early
revascularization andcoronaryarterystenttherapy that mayreduce
LV dysfunction or LV thrombus formation.
The devastating impact of a stroke after an MI, and the
increasing number of persons at risk because of improved post-MI
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with heart disease. Consequently, the effectiveness of anticoagu-
lation therapy after anterior MI for the prevention of stroke
warrants further investigation.
Methods
Study Population
The design of the Enhanced Feedback for Effective Cardiac
Treatment (EFFECT) study has been described previously
[27,28]. The EFFECT study is a large province-wide initiative
designed to improve the quality of acute MI care in Ontario,
Canada. In summary, the EFFECT database consists of a large
population-based sample of acute MI patients hospitalized
throughout Ontario, Canada between April 1, 1999 and March
31, 2001. The hospitals included university-affiliated and com-
munity-based institutions from both rural and urban settings. All
had admitted more than 30 patients with acute MI during the two
years of sampling.
For this study, we excluded patients who had a previously
recorded MI admission within the past year, those who sustained a
MI as an in-hospital complication (e.g. post-operative), those who
were transferred from an outside institution, those younger than
20 or 105 years of age or older, nonresidents of the province of
Ontario, and those with invalid health insurance numbers. We
also excluded those with a history of warfarin use due to previous
atrial fibrillation, valvular disease, carotid endarterectomy, or
thromboembolic disease, because these patients may have had
other indications (other than an anterior MI) for receiving warfarin
post infarction.
For the diagnosis of an acute MI, each patient had to meet the
European Society of Cardiology/American College of Cardiology
clinical criteria for acute MI [29], and its onset must have occurred
before the patient arrived at the hospital.
The records of patients who met the inclusion and exclusion
criteria for the study were reviewed by trained cardiology research
nursesforabstraction ofclinicaldata and processesofcare related to
the index MI hospitalization. Random re-abstraction of charts
indicated high interrater agreement [30]. A random sample of 125
patients was identified among hospitals treating at least 125 suitable
candidates during the study period. For hospitals that treated fewer
than 125 suitable candidates duringthe study period,all charts were
reviewed. Among the 104 acute care hospitals eligible for the study,
103 institutions ultimately participated in the study. A total of
11 524 patients with a most-responsible diagnosis of AMI
(International Classification of Diseases, Ninth Revision, Clinical Modification
[ICD-9] code 410) were identified using the Canadian Institutes of
Health Information (CIHI) hospital discharge abstract database
[27,28]. Additional details related to the exclusion/inclusion criteria
and validation of the AMI coding have been published elsewhere
[27,28,31–33]. Administrative data were linked anonymously using
encrypted individual health card numbers.
Ethics Statement
The study protocol was submitted to and approved by the
research ethics boards at the participating institutions and
Sunnybrook Health Sciences Centre. The research ethics boards
approved a waiver of informed consent for collecting the study
data due to the minimal risk nature of the study [34,35].
Definitions, Study Outcomes and Data Sources
We defined a set of clinical and demographic variables that may
potentially be associated with stroke after MI that were available
from chart review. Patient hospitalizations were identified using
ICD-9 and 10 codes in CIHI hospital discharge abstracts to
longitudinally characterize subsequent events and co-morbid
illnesses (Table S1). We used each patient’s encrypted identifica-
tion number to link hospital discharge data to the Registered
Persons Database (RPDB) in order to calculate mortality. The
RPDB provides data on the vital status of residents of Ontario and
records both in- and out-of-hospital death. The Ontario Drug
Benefits (ODB) database was used to longitudinally identify
medications each participant aged 66 and older was dispensed
during the observation period, from Ontario’s universal drug
benefits plan.
The primary study cohort was those patients who were
diagnosed as having an acute anterior-wall MI, with additional
analyses conducted using the complete data set of all MI survivors.
Anterior location of the MI was defined as a diagnostic
electrocardiogram having either Q-waves or ST-elevation greater
than 1 mm in leads I and aVL or V1 through V4. A subset of the
above cohort (n=1483), those aged 66 and older, was selected to
analyze the effect of out-patient medication use on outcomes.
The primary study outcome was the rate of ischemic stroke
(Table S1) among acute anterior-wall MI patients who survived to
hospital discharge. Secondary outcomes focused on death from
any cause and bleeding-related complications, such as hospital-
ization for gastrointestinal (GI) or cerebral hemorrhage. We
evaluated warfarin use among the entire cohort upon discharge,
and continued warfarin use 30, 60, and 90 days after the index MI
among those aged 66 and older, as the exposure of interest. We
chose to study warfarin use at monthly intervals between discharge
and 90 days in order to determine whether there is a significant
protective effect of longitudinal warfarin use on the rate of stroke
in routine clinical practice among those who take warfarin for any
duration, including up to the guideline-recommended three
months.
Statistical Analysis
The demographic and clinical characteristics of patients with
anterior MI and other types of MI were compared. Dichotomous
variables were compared by the chi-squared test and continuous
variables by the Student’s t-test.
We used Cox proportional-hazards analysis to identify factors
associated with an increased risk of ischemic stroke after
hospitalization for an anterior MI. Candidate variables were
included in the initial Cox regression model if they were associated
with stroke in a univariate analysis (P,0.25). Backward variable
elimination, with an elimination criterion of a P-value of more
than 0.05, was then used to create a parsimonious model for
predicting ischemic stroke. We determined that the assumption of
proportional hazards was met in all Cox regression models.
Survival-free of stroke curves were constructed for warfarin users
and non-users among anterior-wall MI patients.
The results are shown as means 6 SD unless otherwise
indicated. Statistical analysis was performed using SAS version 9.1
(SAS Institute Inc, Cary, NC); a P-value less than 0.05 was
considered statistically significant.
Results
Clinical Characteristics
Among the 11 524 index MI patients assessed for eligibility for
this study, 10 383 patients survived to hospital discharge, of which
2 942 (28%) had an anterior-wall MI (50% or 1483 were patients
aged 66 or older). The clinical characteristics of the study patients
are shown in Table 1. Patients who survived an anterior MI to
dischargewereyounger (65vs. 67years, P,0.001), more likely tobe
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lower incidence of previous MI (20 percent vs. 23 percent P,0.001)
as compared to those who survived other types of MI. Anterior MI
patients were more likely to present with significant left ventricular
dysfunction (defined as an LV ejection fraction ,40% or grade 3 or
4, or narrative description of LV function as ‘‘moderate’’ or
‘‘severe’’) (23 percent vs. 11 percent P,0.001) and had a higher
likelihood of developing a left ventricular aneurysm, thrombus or
ventricular septal defect (5 percent vs. 1 percent P,0.001) as a
complication of the index MI. Upon discharge from hospital,
anterior MI patients were more likely to be prescribed an
anticoagulant (22 percent vs. 12 percent; P,0.001), including
warfarin (14 percent vs. 6 percent; P,0.001), an angiotensin-
converting-enzyme (ACE) inhibitor (59 percent vs. 52 percent;
P,0.001)and clopidogrel (6percentvs.5 percent;P=0.02),butless
likely to be prescribed aspirin (73 percent vs. 77 percent; P,0.001),
calcium antagonists (22 percent vs. 28 percent; P,0.001), and
nitrates (38 percent vs. 44 percent; P,0.001).
Total Incidence of Stroke and Secondary Outcomes
The unadjusted rates of stroke, bleeding, and mortality among
the entire cohort are summarized in Table 2. One hundred and
Table 1. Characteristics of 10,383 Myocardial Infarction Patients Discharged Alive.
Variable Total Anterior MI Other MI P-value
N=10,383 N=2,942 N=7,441
Patient Demographics
Age 66.46613.51 65.52613.75 66.84613.39 ,.001
Male 6,805 (65.5%) 1,976 (67.2%) 4,829 (64.9%) 0.03
Past Medical History
Diabetes mellitus 2,621 (25.2%) 707 (24.0%) 1,914 (25.7%) 0.07
Myocardial infarction 2,333 (22.5%) 595 (20.2%) 1,738 (23.4%) ,.001
Congestive heart failure 418 (4.0%) 120 (4.1%) 298 (4.0%) 0.86
Hypertension 4,692 (45.2%) 1,291 (43.9%) 3,401 (45.7%) 0.09
Previous smoker 2,569 (24.7%) 674 (22.9%) 1,895 (25.5%) 0.007
Previous atrial fibrillation 122 (1.2%) 26 (0.9%) 96 (1.3%) 0.08
Previous ischemic stroke 133 (1.3%) 33 (1.1%) 100 (1.3%) 0.36
In Hospital Findings & Procedures
Peak creatine kinase (CK) .2 times the upper limit of normal 6,293 (60.6%) 1,966 (66.8%) 4,327 (58.2%) ,.001
Killip class $3 248 (2.4%) 82 (2.8%) 166 (2.2%) 0.09
LV dysfunction 1,461 (14.1%) 679 (23.1%) 782 (10.5%) ,.001
LV aneurysm, thrombus, or ventricular septal defect (VSD) 226 (2.2%) 139 (4.7%) 87 (1.2%) ,.001
ST elevation on any lead groups 4,979 (48.0%) 2,474 (84.1%) 2,505 (33.7%) ,.001
Reperfusion therapy 3,414 (32.9%) 1,419 (48.2%) 1,995 (26.8%) ,.001
Discharge systolic blood pressure 120.42619.68 118.01619.39 121.36619.65 ,.001
Discharge diastolic blood pressure 67.89611.62 67.33612.07 68.11611.43 0.002
In-hospital atrial fibrillation 620 (6.0%) 171 (5.8%) 449 (6.0%) 0.67
In-hospital ischemic stroke 20 (0.2%) 7 (0.2%) 13 (0.2%) 0.51
Discharge Medications
ACE inhibitors 5,578 (53.7%) 1,745 (59.3%) 3,833 (51.5%) ,.001
Angiotensin II receptor blocker (ARB) 216 (2.1%) 67 (2.3%) 149 (2.0%) 0.38
Antiarrhythmics or digoxin 1,232 (11.9%) 364 (12.4%) 868 (11.7%) 0.32
Anticoagulants 1558 (15.0%) 640 (21.8%) 918 (12.3%) ,.001
Aspirin 7,877 (75.9%) 2,137 (72.6%) 5,740 (77.1%) ,.001
Beta-adrenergic antagonists 7,021 (67.6%) 2,026 (68.9%) 4,995 (67.1%) 0.09
Calcium antagonists 2,713 (26.1%) 645 (21.9%) 2,068 (27.8%) ,.001
Clopidogrel 529 (5.1%) 173 (5.9%) 356 (4.8%) 0.02
Diuretics 2,593 (25.0%) 725 (24.6%) 1,868 (25.1%) 0.63
Low molecular weight heparin (LMWH) 237 (2.3%) 60 (2.0%) 177 (2.4%) 0.30
Nitrates 4,346 (41.9%) 1,102 (37.5%) 3,244 (43.6%) ,.001
Statins 3,453 (33.3%) 952 (32.4%) 2,501 (33.6%) 0.22
Warfarin 870 (8.4%) 400 (13.6%) 470 (6.3%) ,.001
Data are reported as number (percentage) of patients or mean 6 standard deviation (SD) value unless otherwise specified.
doi:10.1371/journal.pone.0012150.t001
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an anterior-wall MI were diagnosed within 4 years with an acute
ischemic stroke (Table 2). Seven strokes (0.2 percent) occurred in-
hospital, leaving 169 (5.7 percent) stroke events following hospital
discharge, approximately half of which occurred within the first
year of discharge. In univariate analysis, there were no significant
differences between anterior-wall MI patients and all other MI
patients with regard to one- and four-year ischemic stroke rates, as
well as the secondary outcomes of in-hospital, 30-day, 90-day
stroke rate, all-cause mortality, and hospitalization for bleeding-
related complications after one year. These results were similar
after excluding those patients who developed in-hospital atrial
fibrillation after the index MI. Among the 557 elderly patients who
used warfarin for one year, there also was no significant difference
in bleeding-related hospitalizations between MI groups.
Independent Risk Factors for Stroke
To determine risk factors associated with the occurrence of stroke
after anterior MI and, in particular, whether longitudinal warfarin
use had any significant protective effect on stroke occurrence, an
analysis was restricted to those 1483 patients aged 66 and older, who
were eligible for Ontario’s universal drug benefit plan. Compared to
the entire cohort of anterior MI patients, elderly patients were less
frequently male (55 percent vs. 67 percent, P,0.001), more likely to
have prior heart failure (7 percent vs. 4 percent, P,0.01) and
hypertension(50 percent vs. 44percent, P,0.01). Elderlyanterior MI
patients were less likely to be treated with immediate reperfusion
therapy (38 percent vs. 48 percent P,0.001) and had a higher
likelihood of developing in-hospital atrial fibrillation (8 percent vs. 6
percent P,0.001) as a complication of the index MI. Upon discharge
from hospital, elderly anterior MI patients were more likely to be
prescribed an ACE inhibitor (63 percent vs. 59 percent; P,0.01) and
antiarrhythmic therapy or digoxin (18 percent vs. 12 percent;
P,0.01), less likely to be prescribed a beta-blocker (63 percent vs. 69
percent; P,0.01) and statin (27 percent vs. 32 percent; P,0.01), with
similar rates of anticoagulation and aspirin use at discharge.
The unadjusted characteristics of elderly patients, who devel-
oped and did not experience an ischemic stroke within 4 years
after discharge for an anterior MI, are shown in Table 3. Patients
who had a stroke after anterior MI were more likely to have
previous diabetes mellitus (43 percent vs. 25 percent; P,0.001),
higher systolic blood pressure upon discharge (126 mmHg vs.
120 mmHg; P=0.006), develop atrial fibrillation (14 percent vs. 8
percent; P=0.023) as a complication of their index anterior MI,
and less likely to be prescribed an ACE inhibitor (53 percent vs. 63
percent; P=0.02) and beta-blocker (53 percent vs. 64 percent;
P=0.02). There was no significant difference in the rate of
warfarin use, at or after discharge, among patients who developed
and did not experience an ischemic stroke after an anterior MI.
Independent predictors of stroke after anterior MI were
determined by multivariate analysis and are reported in Table 4.
A previous history of diabetes mellitus (hazard ratio [HR], 2.35;
95% confidence interval [CI], 1.63–3.40) and receiving antiar-
rhythmic therapy or digoxin (HR, 1.60; 95% CI, 1.01–2.52) were
independent predictors of stroke following anterior MI. Receiving
a beta-blocker (HR, 0.60; 95% CI, 0.41–0.87) or an ACE inhibitor
(HR, 0.65; 95% CI, 0.44–0.95) upon discharge for anterior MI
were significant protective factors, but warfarin use for up to 90
days post-MI was not (HR, 0.68; 95% CI, 0.37–1.26). Thirty-
seven percent of patients discharged on warfarin were also
prescribed an antiarrhythmic agent or digoxin, representing a
significant interaction (w=0.24, p,0.0001). The adjusted stroke-
free survival analysis in patients surviving an anterior MI
according to warfarin use is shown in Figure 1.
Among the entire cohort who survived to hospital discharge,
independent predictors of ischemic stroke after any type of MI
were determined by univariate and multivariate analysis (Tables 5
and 6). Positive predictors of stroke after MI included older age, a
previous history of hypertension, heart failure, diabetes, prior
stroke, and LV dysfunction complicating the index MI. Coronary
reperfusion therapy, discharge statin therapy, and aspirin were
protective factors, while discharge diuretic therapy increased long-
term stroke risk. The development of in-hospital atrial fibrillation
and discharge on warfarin therapy were not independent
predictors of long-term stroke after MI in this cohort.
Discussion
Among elderly patients newly-hospitalized for an acute anterior-
wall STEMI who survived to hospital discharge, we observed no
Table 2. Outcomes among 10,383 Myocardial Infarction Patients Discharged Alive.
Outcomes Total Anterior MI Other MI P-value
N=10,383 N=2,942 N=7,441
Ischemic Stroke
In-hospital ischemic stroke rate 20 (0.2%) 7 (0.2%) 13 (0.2%) 0.51
30-Day ischemic stroke rate 89 (0.9%) 30 (1.0%) 59 (0.8%) 0.26
90-Day ischemic stroke rate 143 (1.4%) 44 (1.5%) 99 (1.3%) 0.52
1-Year ischemic stroke rate 291 (2.8%) 87 (3.0%) 204 (2.7%) 0.55
4-Year ischemic stroke rate 577 (5.6%) 169 (5.7%) 408 (5.5%) 0.60
Readmission for Bleeding
1-Year readmission for GI hemorrhage 162 (1.6%) 43 (1.5%) 119 (1.6%) 0.61
1-Year readmission for cerebral hemorrhage 20 (0.2%) 7 (0.2%) 13 (0.2%) 0.51
Mortality
1-Year mortality 1,192 (11.5%) 347 (11.8%) 845 (11.4%) 0.53
4-Year mortality 2,514 (24.2%) 688 (23.4%) 1,826 (24.5%) 0.22
Data are reported as number (percentage) of patients or mean 6 standard deviation (SD) value unless otherwise specified.
doi:10.1371/journal.pone.0012150.t002
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Variable Stroke Non-Stroke P-value
N=118 N=1,365
Patient Demography
Age at admission for MI 76.7766.69 76.5266.97 0.71
Male gender 58 (49.2%) 756 (55.4%) 0.19
Past Medical History
Diabetes mellitus 50 (42.4%) 346 (25.3%) ,.001
Myocardial infarction 33 (28.0%) 319 (23.4%) 0.26
Congestive heart failure 8 (6.8%) 92 (6.7%) 0.99
Hypertension 63 (53.4%) 677 (49.6%) 0.43
Previous smoker 32 (27.1%) 363 (26.6%) 0.90
Previous atrial fibrillation 2 (1.7%) 16 (1.2%) 0.62
Previous ischemic stroke 4 (3.4%) 22 (1.6%) 0.16
In Hospital Findings & Procedures
Killip class $3 6 (5.1%) 51 (3.7%) 0.47
LV dysfunction 27 (22.9%) 334 (24.5%) 0.70
LV aneurysm, thrombus, or VSD 6 (5.1%) 67 (4.9%) 0.93
Reperfusion therapy 37 (31.4%) 525 (38.5%) 0.13
In-hospital onset of atrial fibrillation 16 (13.6%) 104 (7.6%) 0.02
In-hospital onset of ischemic stroke 0 (0.0%) 5 (0.4%) 0.51
Discharge systolic blood pressure 126.11625.59 120.47620.31 0.006
Discharge diastolic blood pressure 67.18613.42 66.39612.04 0.51
Discharge Medications
ACE inhibitors 62 (52.5%) 868 (63.6%) 0.017
ARB 2 (1.7%) 41 (3.0%) 0.42
Antiarrhythmic therapy or digoxin 26 (22.0%) 239 (17.5%) 0.22
Aspirin 80 (67.8%) 987 (72.3%) 0.30
Beta-adrenergic antagonists 62 (52.5%) 868 (63.6%) 0.02
Calcium antagonists 35 (29.7%) 335 (24.5%) 0.22
Diuretics 42 (35.6%) 476 (34.9%) 0.88
LMWH 3 (2.5%) 24 (1.8%) 0.54
Nitrates 53 (44.9%) 580 (42.5%) 0.61
Clopidogrel 7 (5.9%) 64 (4.7%) 0.54
Statins 29 (24.6%) 372 (27.3%) 0.53
Warfarin 15 (12.7%) 205 (15.0%) 0.50
Drug Benefit Claims for Warfarin
Within 30-days post discharge 11 (9.3%) 185 (13.6%) 0.19
Within 90-days post discharge 12 (10.2%) 191 (14.0%) 0.25
Data are reported as number (percentage) of patients or mean 6 standard deviation (SD) value unless otherwise specified.
doi:10.1371/journal.pone.0012150.t003
Table 4. Multivariate Model of Four-Year Ischemic Stroke Risk among 1,483 Elderly Patients with Anterior Myocardial Infarction.
Variable Hazard Ratio (95% CI) P-value
Warfarin user for 90 days 0.68 (0.37–1.26) 0.22
Previous diabetes mellitus 2.35 (1.63–3.40) ,.001
Discharged on antiarrhythmic therapy or digoxin 1.60 (1.01–2.52) 0.045
Discharged on an ACE inhibitor 0.65 (0.44–0.95) 0.025
Discharged on beta-adrenergic antagonists 0.60 (0.41–0.87) 0.008
Candidate variables were included in the initial Cox regression model if they were associated with stroke in a univariate analysis (P,0.25) listed in Table 3. Backward
variable elimination, with an elimination criterion of a P value of more than 0.05, was then used to create a parsimonious model for predicting ischemic stroke.
doi:10.1371/journal.pone.0012150.t004
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discharge or for a further 30-, 60-, or 90 days.
The utility of anticoagulation for the prevention of stroke after
anterior MI is unclear. Anticoagulation might prevent the
development of LV thrombus, which once detected is considered
an established risk factor for embolic stroke [7,14,16–25].
However, previous estimates of anterior MI as an independent
risk factor for LV thrombus or stroke have been inconsistent
[5–14,16–25], and information on their propensity for develop-
ment after current standard interventions (e.g. antiplatelet and
fibrinolytic therapy) for acute MI is limited [14]. Some studies
have suggested that LV dysfunction is a stronger predictor of LV
thrombus formation [16,17,21,22] and the development of stroke
[4]. Hence, the 2005 American College of Cardiology/American
Heart Association practice guidelines [15] recommend those with
STEMI complicated by LV dysfunction and extensive regional
wall-motion abnormalities or LV mural thrombus noted on an
imaging study receive a minimum of 3 months of warfarin for
secondary prevention of stroke. There have only been a few small,
non-blinded, randomized trials and observational studies of
warfarin for established LV thrombus after MI for secondary
prevention of systemic emboli, and these have demonstrated
inconsistent results [36–39]. All were conducted before fibrinolytic
and antiplatelet therapy had become routine. Our data suggests
that overall, anterior MI patients do not have a higher risk of
stroke, or death, as compared to other types of MI patients.
No prospective randomized controlled trial using warfarin has
been conducted to study its efficacy after anterior STEMI in
preventing left ventricular thrombus for prevention of stroke. The
Fragmin in Acute Myocardial Infarction trial [40] prospectively
demonstrated that administration of subcutaneous dalteparin
(150 IU/kg body weight every 12 hours) for the duration of
hospital stay after anterior MI reduced the risk of LV thrombus
formation by 37 percent. But this trial was underpowered to
demonstrate a significant effect on stroke and only followed patient
outcomes for 11 days. Administration of subcutaneous heparin
after thrombolysis for a STEMI [12], or alone in anterior STEMI
[41], also did not demonstrate an effect on stroke. In a
retrospective analysis [42], warfarin use in patients with hetero-
geneous causes of chronic left ventricular dysfunction demonstrat-
ed improved survival and risk of hospitalization for heart failure,
but had no effect on stroke.
Meta-analyses of randomized controlled studies of moderate
intensity warfarin with aspirin therapy after acute coronary
syndrome (ACS) have demonstrated a relative risk reduction of
stroke of approximately 40–46%, representing an absolute risk
reduction between 0.5–1.28 percent [43,44]. These studies were
conducted before routine use of coronary artery stenting and, as
warfarin is not considered adequate for preserving stent patency
compared to thienopyridine agents [45,46,47], its use has lost
ground to competing antiplatelet and antithrombin regimens.
Warfarin use after a MI has not become the standard of practice
within North America also due to concerns regarding its cost-
effectiveness [48] and potential bleeding complications [49]. Stroke
outcomes after MI may still change as practice patterns incorporate
new guidelines based on studies that demonstrated benefit in
combined cardiovascular endpoints with the use of various
antithrombin agents [50,51,52] and newer antiplatelet agents
[53,54] throughout the index hospitalization after acute MI.
Patients who developed stroke after MI were older, had
previous hypertension, heart failure, diabetes, prior stroke, and
LV dysfunction complicating their index MI (Table 6), in keeping
with well established risk factors for stroke following MI. These
observations reinforce that secondary prevention efforts should
focus on identifying and treating these risk factors for stroke, prior
to hospital discharge as opposed to routine pre-emptive anticoag-
ulation of all anterior MI patients. For instance, ACE inhibitor
[55,56,57,58] and beta-blocker [59,60,61,62] therapy after acute
MI complicated by congestive heart failure or LV dysfunction has
demonstrated a 15–20% relative risk reduction in mortality and
cardiovascular morbidity within stable patients. Whether a specific
class of antihypertensive therapy offers additional protection
against stroke post-MI, particularly in prevention of atrial
fibrillation, has yet to be determined [63].
A major strength of our study was the longitudinal analysis of
medication use and consideration of relative indications for
Figure 1. Adjusted Ischemic Stroke-Free Survival among 1,483 Elderly Patients with Anterior Myocardial Infarction. Survival curves
are stratified by warfarin use for up to 90 consecutive days after an anterior MI. The curve in pink represents patients prescribed warfarin (patient
received one or more prescriptions for warfarin after discharge). The curve in blue represents patients not prescribed warfarin.
doi:10.1371/journal.pone.0012150.g001
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atrial dysrhythmia. We also considered relative contraindications
to, and complications from, anticoagulation therapy, such as
major bleeding that required hospitalization. Our research has
some limitations that merit emphasis. Our study was a population-
based cohort analysis, and as such has inherent limitations and
survival bias associated with its retrospective nature and lack of
randomization. As well, the elderly cohort of anterior MI patients
who survived to hospital discharge may not represent the general
post-MI population. Because we used administrative data to
measure stroke outcomes, we were limited in the amount of
clinical information regarding the nature of each outcome. For
instance, left ventricular ejection fraction data was only available
for approximately half of the entire EFFECT cohort. We cannot
ascertain data on the development of conditions that did not
require hospitalization, such as out-of-hospital atrial fibrillation,
stroke or hemorrhage, which may have occurred over the 4 year
period, and as such our study may be underpowered due to the
limited number of stroke hospitalizations. Ischemic stroke
etiologies vary, and may be from causes other than cardioembo-
lism, such as large artery atherosclerosis or small-vessel lacunar
disease. In addition, we cannot ascertain the appropriateness of
warfarin therapy, intensity of anticoagulation, or compliance in
individual patients. For instance, our observation that a significant
Table 5. Characteristics of Patients Diagnosed with Ischemic Stroke among 10,383 Patients within Four Years of Hospital
Discharge for Myocardial Infarction.
Variable Total Stroke Non-Stroke P-value
N=10,383 N=577 N=9,806
Patient Demographics
Age at admission of MI 66.35613.52 73.01610.32 65.96613.59 ,.001
Male gender 6,670 (64.2%) 307 (53.2%) 6,363 (64.9%) ,.001
Past Medical History
Diabetes mellitus 2,576 (24.8%) 226 (39.2%) 2,350 (24.0%) ,.001
Myocardial infarction 2,273 (21.9%) 166 (28.8%) 2,107 (21.5%) ,.001
Congestive heart failure 410 (4.0%) 45 (7.8%) 365 (3.7%) ,.001
Hypertension 4,570 (44.0%) 319 (55.3%) 4,251 (43.4%) ,.001
Previous smoker 2,522 (24.3%) 144 (25.0%) 2,378 (24.3%) 0.73
Previous atrial fibrillation 118 (1.1%) 16 (2.8%) 102 (1.0%) ,.001
Previous ischemic stroke 131 (1.3%) 24 (4.2%) 107 (1.1%) ,.001
In Hospital Findings & Procedures
Anterior wall myocardial infarction 2,942 (28.3%) 169 (29.3%) 2773 (28.2%) 0.60
Peak CK .2 times the upper limit of normal 6,148 (59.2%) 318 (55.1%) 5,830 (59.5%) 0.028
Killip class $3 239 (2.3%) 18 (3.1%) 221 (2.3%) 0.182
LV dysfunction 1,392 (13.4%) 104 (18.0%) 1,288 (13.1%) ,.001
LV aneurysm, thrombus, or VSD 214 (2.1%) 14 (2.4%) 200 (2.0%) 0.53
In-hospital onset of atrial fibrillation 588 (5.7%) 52 (9.0%) 536 (5.5%) ,.001
ST elevation on any lead groups 4,852 (46.7%) 236 (40.9%) 4,616 (47.1%) 0.003
Reperfusion therapy 3,300 (31.8%) 125 (21.7%) 3,175 (32.4%) ,.001
Discharge systolic blood pressure 120.38619.62 125.12622.90 120.11619.38 ,.001
Discharge diastolic blood pressure 67.88611.62 68.64612.50 67.84611.57 0.12
Discharge Medications
ACE Inhibitors 5,449 (52.5%) 319 (55.3%) 5,130 (52.3%) 0.187
ARB 213 (2.1%) 13 (2.3%) 200 (2.0%) 0.73
Antiarrhythmic therapy or digoxin 1,190 (11.5%) 105 (18.2%) 1,085 (11.1%) ,.001
Aspirin 7,734 (74.5%) 385 (66.7%) 7,349 (74.9%) ,.001
Beta-adrenergic antagonists 6,880 (66.3%) 337 (58.4%) 6,543 (66.7%) ,.001
Calcium antagonists 2,659 (25.6%) 167 (28.9%) 2,492 (25.4%) 0.065
Diuretics 2,510 (24.2%) 213 (36.9%) 2,297 (23.4%) ,.001
LMWH 232 (2.2%) 9 (1.6%) 223 (2.3%) 0.26
Nitrates 4,245 (40.9%) 271 (47.0%) 3,974 (40.5%) 0.003
Clopidogrel 511 (4.9%) 26 (4.5%) 485 (4.9%) 0.62
Statin 3,380 (32.6%) 131 (22.7%) 3,249 (33.1%) ,.001
Warfarin 850 (8.2%) 66 (11.4%) 784 (8.0%) 0.004
Data are reported as number (percentage) of patients or mean 6 standard deviation (SD) value unless otherwise specified.
doi:10.1371/journal.pone.0012150.t005
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concomitantly discharged on an antiarrhythmic agent or digoxin,
may suggest that many of these patients developed atrial
dysrhythmia, a well-known immediate post-MI complication,
and may be appropriately anticoagulated. Finally, we cannot
exclude a short-term benefit from anticoagulation during the acute
hospitalization phase post-MI as the number, and information on
the timing, of stroke prior to discharge is limited.
In conclusion, among elderly patients who survive an anterior-
wall MI, there may be no benefit from the routine use of warfarin
up to 90 days post-MI in preventing ischemic stroke. Many
practitioners still consider a large anterior-wall MI as high risk for
potential LV thrombus formation and stroke. Our data would
suggest that routine anticoagulation of patients with anterior-wall
MI may not be indicated, although certain high-risk subgroups
(e.g. documented LV thrombus or atrial fibrillation) may benefit
from warfarin administration in this setting. Prospective random-
ized trials focusing on alternative antithrombin or antiplatelet
strategies are needed to determine the best method for preventing
this common and serious adverse outcome.
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